ESSA Pharma Advances Prostate Cancer Clinical Trials

WisdomTree India Earnings Fund (EPI) has released an update.

ESSA Pharma Inc. reports steady progress in their clinical trials for treating prostate cancer, with key milestones expected in the upcoming months. They have a healthy cash runway to fund operations beyond 2025, and are on track to present significant trial data in the second half of 2024, including Phase 1 masofaniten plus enzalutamide dose escalation study results and Phase 1b monotherapy results.

For further insights into EPI stock, check out TipRanks’ Stock Analysis page.